No Data
Investor Optimism Abounds Hangzhou Minsheng Healthcare Co., Ltd. (SZSE:301507) But Growth Is Lacking
Minsheng Health (301507.SZ): The new Business will simultaneously develop the OTC products and health products lines.
On February 20, Gelonghui reported that in a recent investor relations activity, Minsheng Health (301507.SZ) mentioned that due to the company's later entry into the health products sector compared to OTC, it has not yet formed a sizable sales scale. However, the sales of health products maintain a high growth rate, and their proportion in the company's business revenue is gradually increasing. The company will simultaneously establish its new business in both OTC products and health products, so the product structure proportion will be dynamically adjusted according to the actual business development and market demand to ensure healthy business growth and achieve optimal allocation of company resources.
Mins Health (301507.SZ): The primary sales channel for Aluminum magnesium carbonate suspension is concentrated in offline pharmacy terminals, and it is currently in the招商 and distribution stage.
On February 20, Gelonghui reported that Minsheng Health (301507.SZ) recently indicated in its investor relations activities that Magnesium Carbonate Aluminum Suspension, as a therapeutic OTC product, has its main sales channel concentrated in offline pharmacy terminals, and is currently in the stages of recruitment and distribution. The current Orders for this product are stable, but due to outsourced production, the manufacturers face certain pressures with deliveries due to the Spring Festival holiday and production scheduling. This situation is expected to be a short-term phenomenon, and it is anticipated that the product's delivery status will improve quickly.
Mingsheng Health (301507.SZ): Obtained the pharmaceutical approval for Tartrate Varenicline tablets.
On February 13, GF Securities reported that Minsheng Health (301507.SZ) announced that recently, Hangzhou Minsheng Health Pharmaceutical Co., Ltd. received the approval notice for the supplemental application of varenicline tartrate tablets issued by the National Medical Products Administration. Varenicline tartrate tablets are used for smoking cessation in adults. Varenicline is a selective partial agonist of the nicotinic acetylcholine receptor α4β2 subtype, with high affinity for this receptor in the nervous system. Varenicline binds to the α4β2 receptor to produce agonistic effects while blocking nicotine from binding to this receptor, thereby facilitating smoking cessation.
Hangzhou Minsheng Healthcare (SZSE:301507) Will Want To Turn Around Its Return Trends
Minsheng Health (301507.SZ): The company and its wholly-owned subsidiary received a certificate for an invention patent.
On December 24, Gelonghui reported that Minsheng Health (301507.SZ) announced that recently, the company and its wholly-owned subsidiary Minsheng Zhongke Jiayi (Zhejiang) Biotechnology Co., Ltd. (formerly Zhejiang Minsheng Health Technology Co., Ltd.) received a certificate of invention patent issued by the National Intellectual Property Administration. The invention is titled "A method for extracting Vitamin K2 from a composite formulation of various Vitamins and Minerals," with a patent term of twenty years.
